References
- Daoud MS, Dicken CH. Apocrine glands. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors, Fitzpatrick’s Dermatology in General Medicine, 5th edn, vol 1. McGraw-Hill: New York, 1999:814–17.
- Geren SM, Kerdel KA, Falabella AF, Kirsner RS. Infliximab: a treatment option for ulcerative pyoderma gangrenosum. Wounds 2003;15:49–53.
- Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003;49:S275–6.
- Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn’s disease: response to treatment with infliximab. Inflamm Bowel Dis 2001;7:323–6.
- Hull KM, Shoham N, Chae JJ, et al. The expanding spec- trum of systemic autoinflammatory disorders and theirrheu- matic manifestations. Curr Opin Rheumatol 2003;15:61–9.
- Kastner DL, O’Shea JJ. A fever gene comes in from the cold. Nat Genet 2001;29:241–2.
- Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 2002;81:349–68.
- Drewe E, McDermott EM, Powell PT, et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and ase study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology 2003;42:235–9.
- Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent path- way. Gastroenterology 2001;121:1145–57.
- Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002;11:961–9.
- Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997;72:611–15.
- Bhalla R, Sequeira W. Arthritis associated with hidradenitis suppurativa. Ann Rheum Dis 1994;53:64–6.
- Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985;55:173–86.
- Rosner IA, Burg CG, Wisnieski JJ, et al. The clinical spectrum of the arthropathy associated with hidradenitis suppurativa and acne conglobata. J Rheumatol 1993;20:684–7.
- Ostlere LA, Langtry JAA, Mortimer PS, Staughton RCD. Hidradenitis suppurativa in Crohn’s disease. Br J Dermatol 1991;125:384–6.
- Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001;411:603–6.
- Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001;29:19–20.
- Von der Werth JM, Williams HC, Raeburn JA. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol 2000;142:947–53.